Epizyme (EPZM) Misses Q4 EPS by 4c

Epizyme (NASDAQ: EPZM) reported Q4 EPS of ($0.49), $0.04 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $18.63 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c